| Trastuzumab deruxtecan (T-DXd) in patients with HER2-mutant metastatic non–small cell lung cancer (mNSCLC): Final analysis results of DESTINY-Lung02. PA Janne, Y Goto, T Kubo, K Ninomiya, SW Kim, D Planchard, MJ Ahn, ... Journal of Clinical Oncology 42 (16_suppl), 8543-8543, 2024 | | 2024 |
| Recommendations for reporting tissue and circulating tumour (ct) DNA next-generation sequencing results in non-small cell lung cancer U Malapelle, N Leighl, A Addeo, D Hershkovitz, MJ Hochmair, O Khorshid, ... British Journal of Cancer, 1-8, 2024 | | 2024 |
| 267MO Pooled analysis of trastuzumab deruxtecan (T-DXd) retreatment (RTx) after recovery from grade (Gr) 1 interstitial lung disease/pneumonitis (ILD) HS Rugo, E Tokunaga, H Iwata, V Petry, EF Smit, Y Goto, DW Kim, ... ESMO Open 9, 2024 | | 2024 |
| The optimal treatment for patients with stage I non-small cell lung cancer: minimally invasive lobectomy versus stereotactic ablative radiotherapy–a nationwide cohort study JC de Ruiter, V van der Noort, JNA van Diessen, EF Smit, RAM Damhuis, ... Lung Cancer 191, 107792, 2024 | 1 | 2024 |
| Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC HA Yu, C Baik, DW Kim, ML Johnson, H Hayashi, M Nishio, JCH Yang, ... Annals of Oncology 35 (5), 437-447, 2024 | 3 | 2024 |
| Antibody-drug conjugates in lung and breast cancer: Current evidence and future directions–a position statement from the ETOP IBCSG Partners Foundation S Peters, S Loi, F André, S Chandarlapaty, E Felip, SP Finn, PA Jänne, ... Annals of Oncology, 2024 | | 2024 |
| BRAFV600E-mutant metastatic NSCLC: disease overview and treatment landscape D Planchard, RE Sanborn, MV Negrao, A Vaishnavi, EF Smit NPJ Precision Oncology 8 (1), 90, 2024 | | 2024 |
| Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): Primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial EF Smit, E Felip, D Uprety, M Nagasaka, K Nakagawa, LPA Rodríguez, ... The Lancet Oncology 25 (4), 439-454, 2024 | 2 | 2024 |
| Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access Protocol K Verkerk, BS Geurts, LJ Zeverijn, V van der Noort, HMW Verheul, ... The Lancet Regional Health–Europe 39, 2024 | 1 | 2024 |
| Osimertinib Plasma Trough Concentration in Relation to Brain Metastases Development in Patients With Advanced EGFR-Mutated NSCLC JL Gulikers, GDM Veerman, M Jebbink, PD Kruithof, CMJ Steendam, ... JTO Clinical and Research Reports 5 (4), 100656, 2024 | | 2024 |
| Ex vivo 3D micro tumor testing to assess chemotherapy and immunotherapy responses for NSCLC patients E Koedoot, TJ Sijsenaar, LJ Ceton, DJ van der Meer, TJ van Brakel, ... Cancer Research 84 (6_Supplement), 6396-6396, 2024 | | 2024 |
| A phase 2 trial combining afatinib with cetuximab in patients with EGFR exon 20 insertion–positive non–small cell lung cancer BAMH van Veggel, AJ van der Wekken, MS Paats, LEL Hendriks, ... Cancer 130 (5), 683-691, 2024 | 1 | 2024 |
| Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer J van de Haar, JM Mankor, K Hummelink, K Monkhorst, EF Smit, ... Clinical Cancer Research, OF1-OF12, 2024 | 3 | 2024 |
| Survival difference between patients with single versus multiple metastatic lymph nodes and the role of histology in pathological stage II-N1 non-small cell lung cancer J Ruiter, A de Langen, K Monkhorst, A Veenhof, H Klomp, J Smit, E Smit, ... Acta Chirurgica Belgica, 1-12, 2024 | | 2024 |
| A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non–small Cell Lung Cancer That Is Suitable for Routine Clinical Diagnostics K Hummelink, R Tissier, LJW Bosch, O Krijgsman, MM Van den Heuvel, ... Clinical Cancer Research 30 (4), 814-823, 2024 | | 2024 |
| A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer GJ Riely, EF Smit, MJ Ahn, E Felip, SS Ramalingam, A Tsao, M Johnson, ... Future Oncology, 2024 | | 2024 |
| Selpercatinib or Chemotherapy in RET Fusion-Positive NSCLC AMC Dingemans, EF Smit, LEL Hendriks The New England journal of medicine 390 (4), 381, 2024 | | 2024 |
| Treatment decision for recurrences in non-small cell lung cancer during or after adjuvant osimertinib: an international Delphi consensus report M Mirza, A Shrivastava, C Matthews, N Leighl, CSH Ng, D Planchard, ... Frontiers in Oncology 13, 1330468, 2024 | | 2024 |
| Tertiary lymphoid structure-related immune infiltrates in NSCLC tumor lesions correlate with low tumor-reactivity of TIL products SM Castenmiller, N Kanagasabesan, A Guislain, B Nicolet, M van Loenen, ... bioRxiv, 2024.02. 19.580998, 2024 | | 2024 |
| Blood platelet RNA profiles do not enable for nivolumab response prediction at baseline in patients with non-small cell lung cancer M Muller, MG Best, V van der Noort, TJN Hiltermann, ALN Niemeijer, ... Tumor Biology 46 (s1), S327-S340, 2024 | 2 | 2024 |
Pieter PostmusLUMC在 lumc.nl 的电子邮件经过验证
Pieter PostmusLUMC在 lumc.nl 的电子邮件经过验证